Literature DB >> 30602591

Inflammatory Macrophages in the Sciatic Nerves Facilitate Neuropathic Pain Associated with Type 2 Diabetes Mellitus.

Fumihiro Saika1, Norikazu Kiguchi2, Shinsuke Matsuzaki1, Daichi Kobayashi1, Shiroh Kishioka1.   

Abstract

Despite the requirement for effective medication against neuropathic pain associated with type 2 diabetes mellitus (T2DM), mechanism-based pharmacotherapy has yet to be established. Given that long-lasting neuroinflammation, driven by inflammatory macrophages in the peripheral nerves, plays a pivotal role in intractable pain, it is important to determine whether inflammatory macrophages contribute to neuropathic pain associated with T2DM. To generate an experimental model of T2DM, C57BL/6J mice were fed a high-fat diet (HFD) ad libitum. Compared with control diet feeding, obesity and hyperglycemia were observed after HFD feeding, and the mechanical pain threshold evaluated using the von Frey test was found to be decreased, indicating the development of mechanical allodynia. The expression of mRNA markers for macrophages, inflammatory cytokines, and chemokines were significantly upregulated in the sciatic nerve (SCN) after HFD feeding. Perineural administration of saporin-conjugated anti-Mac1 antibody (Mac1-Sap) improved HFD-induced mechanical allodynia. Moreover, treatment of Mac1-Sap decreased the accumulation of F4/80+ macrophages and the upregulation of inflammatory mediators in the SCN after HFD feeding. Inoculation of lipopolysaccharide-activated peritoneal macrophages in tissue surrounding the SCN elicited mechanical allodynia. Furthermore, pharmacological inhibition of inflammatory macrophages by either perineural or systemic administration of TC-2559 [4-(5-ethoxy-3-pyridinyl)-N-methyl-(3E)-3-buten-1-amine difumarate], a α4β2 nicotinic acetylcholine receptor-selective agonist, relieved HFD-induced mechanical allodynia. Taken together, inflammatory macrophages that accumulate in the SCN mediate the pathophysiology of neuropathic pain associated with T2DM. Inhibitory agents for macrophage-driven neuroinflammation could be potential candidates for novel pharmacotherapy against intractable neuropathic pain.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30602591     DOI: 10.1124/jpet.118.252668

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Targeting Neuroimmune Interactions in Diabetic Neuropathy with Nanomedicine.

Authors:  Mihály Balogh; Jelena M Janjic; Andrew J Shepherd
Journal:  Antioxid Redox Signal       Date:  2022-01       Impact factor: 8.401

2.  Treatment-Induced Neuropathy in Diabetes (TIND)-Developing a Disease Model in Type 1 Diabetic Rats.

Authors:  Petra Baum; Severin Koj; Nora Klöting; Matthias Blüher; Joseph Classen; Sabine Paeschke; Martin Gericke; Klaus V Toyka; Marcin Nowicki; Joanna Kosacka
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

3.  Dimethyl Itaconate Attenuates CFA-Induced Inflammatory Pain via the NLRP3/ IL-1β Signaling Pathway.

Authors:  Jiaqi Lin; Jinxuan Ren; Bin Zhu; Yi Dai; Dave Schwinn Gao; Suyun Xia; Zhenzhen Cheng; Yangyuxin Huang; Lina Yu
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

Review 4.  Cytotoxic Immunity in Peripheral Nerve Injury and Pain.

Authors:  Alexander J Davies; Simon Rinaldi; Michael Costigan; Seog Bae Oh
Journal:  Front Neurosci       Date:  2020-02-21       Impact factor: 4.677

5.  Electroacupuncture alleviates diabetic neuropathic pain in rats by suppressing P2X3 receptor expression in dorsal root ganglia.

Authors:  Xueyu Fei; Xiaofen He; Zhaoxia Tai; Hanzhi Wang; Siying Qu; Luhang Chen; Qunqi Hu; Jianqiao Fang; Yongliang Jiang
Journal:  Purinergic Signal       Date:  2020-10-03       Impact factor: 3.765

6.  Tracking macrophages in diabetic neuropathy with two-color nanoemulsions for near-infrared fluorescent imaging and microscopy.

Authors:  James M Nichols; Caitlin V Crelli; Lu Liu; Hoang Vu Pham; Jelena M Janjic; Andrew J Shepherd
Journal:  J Neuroinflammation       Date:  2021-12-23       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.